{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:20Z","timestamp":1793734220868,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.11.017","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T17:15:36Z","timestamp":1542302136000},"page":"151-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Tardive dyskinesia: Who gets it and why"],"prefix":"10.1016","volume":"59","author":[{"given":"Karen","family":"Frei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.11.017_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes","volume":"389","author":"Frei","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib2","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia. Baseline data for the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib9","first-page":"27","article-title":"Tardive dyskinesia in older patients","volume":"61","author":"Jeste","year":"2000","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mds.20259","article-title":"Metoclopramide-induced tardive dyskinesia in an infant","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/gps.4399","article-title":"Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis","volume":"31","author":"O'Brien","year":"2016","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1176\/ajp.156.2.309","article-title":"Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients","volume":"156","author":"Jeste","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib14","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"803","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","article-title":"Antipsychotic-induced movement disorders in the elderly","volume":"17","author":"Caligiuri","year":"2000","journal-title":"Drugs Aging"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0447.1999.tb07227.x","article-title":"Tardive dyskinesia in psychosis: are women really more at risk? UK 700 group","volume":"99","author":"van Os","year":"1999","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib18","first-page":"28","article-title":"Genetics of tardive dyskinesia: promising leads and ways forward","volume":"389","author":"Zai","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pnpbp.2017.04.030","article-title":"Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms","volume":"78","author":"Miksys","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/0269881114523861","article-title":"Association of tardive dyskinesia with variation in CYP2D6: is there a role for active metabolites?","volume":"28","author":"Koola","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01213011-200503000-00003","article-title":"CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis","volume":"15","author":"Patsopoulos","year":"2005","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.mp.4002023","article-title":"Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients","volume":"12","author":"Zai","year":"2007","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","article-title":"Antipsychotic induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta-analysis","volume":"83","author":"Bakker","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajmg.b.30946","article-title":"The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia","volume":"153B","author":"Tsai","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/187569211795508448","article-title":"Ethical and policy considerations in the application of pharmacogenetic testing for tardive dyskinesia: case study of dopamine D3 receptor","volume":"9","author":"Shamy","year":"2011","journal-title":"Curr. Pharmacogenomics Personalized Med. (CPPM)"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","article-title":"Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia","volume":"6","author":"Segman","year":"2001","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.mp.4000847","article-title":"Lack of association between serotonin 2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia","volume":"6","author":"Basile","year":"2001","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","article-title":"Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats","volume":"219","author":"Creed-Carson","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ajmg.b.30981","article-title":"A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial","volume":"153B","author":"Tsai","year":"2010","journal-title":"Am. J. Med. Genet. B"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jpsychires.2013.07.025","article-title":"Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia","volume":"47","author":"Zai","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","article-title":"Oxidative stress and tardive dyskinesia: pharmocogenetic evidence","volume":"46","author":"Cho","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4002142","article-title":"Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions","volume":"13","author":"Bakker","year":"2008","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib33","article-title":"Meta-analyses of manganese superoxide dismutase activity, gene Ala-9Val polymorphism, and the risk of schizophrenia","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/npp.2009.220","article-title":"Association of the HSPG 2 gene with neuroleptic-induced tardive dyskinesia","volume":"35","author":"Syu","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/tpj.2011.32","article-title":"Support for an association of HSPG 2 with tardive dyskinesia in caucasian patients","volume":"12","author":"Greenbaum","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2018.00974","article-title":"Investigation of the HSPG 2 gene in tardive dyskinesia- New data and meta-analysis","volume":"9","author":"Zai","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib37","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1046\/j.1471-4159.1994.62031112.x","article-title":"Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake","volume":"62","author":"Ben-Shachar","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2018.11.017_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5334\/tohm.165","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"12","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov (NY)"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00023210-200317010-00004","article-title":"Oxidated mechanisms and tardive dyskinesia","volume":"17","author":"Lohr","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.02.011","article-title":"Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia","volume":"44","author":"Seeman","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.017_bib41","article-title":"Vitamin E for antipsychotic \u2013 induced tardive dyskinesia","volume":"1","author":"Soares-Weiser","year":"2018","journal-title":"Cocharne Database Syst. Rev."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T12:12:34Z","timestamp":1720786354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":41,"alternative-id":["S1353802018305157"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.017","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tardive dyskinesia: Who gets it and why","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}